论文部分内容阅读
心律平(Propafenone,PF)最初由西德研制,并于197(?)年开始在西德和欧洲临床广泛使用,是属 IC 类抗心律失常药。我国1979年首先由广州研制成功,并于1982年6月通过鉴定。该药最大特点是对室性、室上性及其它快速型心律失常有效,治疗血浓度范围大;毒副反应小,既可口服又可静脉给药。近年来,我国各地医院都相继进行了临床试用,亦积累了不少成功经验,但目前国内外关于PF 与其它药物相互作用的报告少且零散,为更合
Propafenone (PF) was originally developed by West Germany and was widely used in clinical practice in West Germany and Europe since 197 (?) Year. It is an IC antiarrhythmic drug. In 1979, China first successfully developed by Guangzhou, and in June 1982 passed the appraisal. The most prominent feature of the drug is ventricular, supraventricular and other rapid arrhythmia effective blood concentration range; small side effects, both oral and intravenous administration. In recent years, hospitals in our country have carried out clinical trials one after another, and also accumulated a lot of successful experiences. However, there are few reports about the interaction between PF and other drugs both at home and abroad,